INTRODUCTION
============

Skin cancer is the most common malignant disease. Basal cell carcinomas (BCC) and cutaneous squamous cell carcinomas (cSCC) are the major histological types of nonmelanoma skin cancer. cSCC is more aggressive than BCC and is often locally recurrent and sometimes metastasizes to local and locoregional lymph nodes. In contrast, metastasis of BCC is very rare with an incidence of less than 0.01% \[[@b1-ceo-2019-00192],[@b2-ceo-2019-00192]\]. BCCs are prone to locally aggressive growth with invasion of the soft tissue, cartilage, and bone. Approximately 75%--80% of BCC occur in the head and neck region \[[@b3-ceo-2019-00192]\]. In contrast, cSCC has shifted from the head and neck to the extremities in the last decades. However, the incidence of both BCC and cSCC in the head and neck is rapidly increasing. This is attributed to genetic factors, excessive exposure to radiation (ultraviolet B-rays \[UVB\], artificial, and natural radiation), and prolonged life expectancy \[[@b4-ceo-2019-00192]-[@b6-ceo-2019-00192]\]. The prognosis of BCC and cSCC depends on tumor localization, surgical margins, histological subtype, gene expression, immunosuppression, previous incomplete treatment, and recurrence \[[@b7-ceo-2019-00192]\].

BCC and cSCC are often highly aggressive and destructive, especially in the orbit and nose; therefore a combination of optimal tumor control and best possible cosmesis after surgery is very important. Therapies for BCC and cSCC of the nose include surgery with rehabilitation, primary radiochemotherapy, brachytherapy, or a combination of treatments \[[@b8-ceo-2019-00192]-[@b14-ceo-2019-00192]\]. Moreover, recurrent or unresectable BCC can be treated with Vismodegib. The nose is a prominent landmark in the center of the face, has a complex three-layered structure (skin, cartilage or bone, and mucosa) and has three-dimensional contours, which makes reconstructing the nose a challenge for the head and neck surgeon \[[@b15-ceo-2019-00192],[@b16-ceo-2019-00192]\]. Rehabilitation after ablation may be achieved by surgical reconstruction with autologous material or by fitting a bone-anchored nasal prosthesis. The type of rehabilitation depends on the tumor stage and biology, as well as the wishes of the patient. Nasal dysfunction or an unsatisfactory aesthetic outcome may occur after reconstruction of multilayered nasal defects. Although the reconstruction of superficial tumors with skin defects can also be challenging, in this study we only investigate deep infiltrating and multilayered tumors \[[@b17-ceo-2019-00192],[@b18-ceo-2019-00192]\].

To our knowledge, the different rehabilitation options in nasal skin cancer (NSC) patients with extensive multilayered defects have not been investigated alone so far. In this single center study, we compared patients' Health-related quality of life (HRQoL) following the reconstruction of extended defects after nasal cancer resection by plastic reconstruction versus use of an implant-retained prosthesis.

MATERIALS AND METHODS
=====================

This study was performed in accordance with the guidelines of the Declaration of Helsinki on biomedical research involving human subjects, and the study protocol was approved by the local Ethics Committee of Medical Faculty, Heidelberg University Hospital, and informed consent for study and publication was obtained from all individual participants included in the study.

Nasal cancer patients with newly diagnosed nonmelanoma NSC requiring ablative surgery resulting in extensive multilayered nasal defects at the Department of Otolaryngology, Head and Neck Surgery at the Heidelberg University Hospital between 2003 and 2013 were included in the study \[[@b19-ceo-2019-00192]\]. Patients with cancer of the nasal vestibule or nasal cavity were excluded \[[@b20-ceo-2019-00192]\]. Treatment options were discussed by a multidisciplinary tumor board. In accordance with National Comprehensive Cancer Network guidelines, surgical resection was the preferred treatment option. A detailed presurgical clinical examination with complete skin inspection to exclude other malignant skin tumors was performed by experienced physicians (KZ and PAF), together with ultrasound examination of the neck. An additional computed tomography (CT) scan of the mid-face with thin-sliced images was performed for advanced tumors. A complementary CT of the neck and thorax and ultrasound examination of the abdomen was used for staging. Tumor resection was performed by diathermy to reduce bleeding and to avoid the need for vasoconstrictor agents. Depending on tumor localization, extension, and infiltration depth, a two-layer resection (skin and cartilage/bone), or full thickness (three-layer) excision was carried out by a partial or total rhinectomy. Selective neck dissection was performed in the cSCC group in suspected cervical lymph node metastases only. Aesthetic and functional rehabilitation was achieved by surgical multi-layer reconstruction or prosthetic restoration. Depending on the tumor stage, Karnofsky performance status and age (older patients often preferred a prosthetic restoration), the reconstruction methods were discussed with the patient. The preferred method for surgical reconstruction was the paramedian forehead flap to meet the subunit principle. Surgery was performed by the senior surgeon (PAF).

For all patients, clinical and follow-up data (sex, age, TNM classification, histopathological differentiation, treatment modalities, and outcome) were recorded. Tumors were staged according to the Union for International Cancer Control (eighth edition). Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) were statistically estimated by the Kaplan-Meier method using IBM SPSS ver. 22.0 (IBM Corp., Armonk, NY, USA).

Patients completed one generic questionnaire (36-Item Short Form Health Survey \[SF-36\]) and two organ-specific questionnaires (Rhinoplasty Outcome Evaluation \[ROE\] and Functional Rhinoplasty Outcome Inventory 17 \[FROI-17\]) after treatment between 2013 and 2015. The SF-36 Health Survey is composed of eight subgroups: physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning, and mental health (scales and scoring are reflected in the SF-36 Health Survey Manual and Interpretation Guide). The ROE is composed of six items and focuses more on aesthetic aspects. A higher ROE score indicates higher satisfaction. The FROI-17 contains 17 items and measures more functional aspects \[[@b21-ceo-2019-00192],[@b22-ceo-2019-00192]\]. A higher FROI-17 score indicates less satisfaction. Differences between subgroups were tested by log-rank, analysis of variance, Levene's, and *t*-tests. In all statistical tests, a P-value ≤0.05 was considered statistically significant.

RESULTS
=======

Twenty-five patients were included in the analysis. Baseline patient characteristics are presented in [Table 1](#t1-ceo-2019-00192){ref-type="table"}. Patient age ranged from 52 years to 93 years, with a mean age of 73 years. The sex ratio was 1.5 in favor of men (10 women and 15 men). Five out of 25 patients were diagnosed with a cSCC (20%) and 20 of 25 with a BCC (80%) of the nose. Four out of five cSCCs (80%) were moderately differentiated (grade G2) and for one cSCC (20%), no differentiation was given (Gx). One cSCC was staged as pT1 (20%) and the remaining four as pT3 (80%). For BCC of the nose, 12 of 20 (60%) were classified as pT1, four of 20 (20%) as pT2, three of 20 (15%) as pT3, and one of 20 (5%) as pT4a ([Table 1](#t1-ceo-2019-00192){ref-type="table"}). Five tumors were removed by two-layer skin and cartilage/bone resections, which preserved the mucosal layer. Twenty tumors needed full thickness, three-layered resections with 13 partial and seven total rhinectomies. In 18 of 25 patients (72%), nasal reconstruction was performed using a paramedian forehead flap. These 18 patients had a two-layer defect in five of 18 cases (27.8%) and a three-layer defect in 13 of 18 cases (72.2%). The inner lining and framework of the 13 three-layer defects was reconstructed using an anterior septal mucoperichondrious flap together with conchal cartilage grafts. Seven out of 25 (28%) patients were fitted with an implant-retained nasal prosthesis using the Epiplating implant system (Medicon eG, Tuttlingen, Germany) ([Fig. 1](#f1-ceo-2019-00192){ref-type="fig"}). No major postoperative complications were observed in our cohort (prosthetic rehabilitated or surgical reconstructed patients).

All resections achieved a histopathological R0 resection. In one cSCC patient with suspected lymph node status (based on imaging), a concomitant bilateral neck dissection was performed and resulted in a pN0 classification. Two out of five cSCC patients (40%) had advanced stage tumors with infiltration of the upper lip and/or premaxillary bone, therefore received adjuvant radiation therapy.

The median follow-up time was 2.1 years (range, 0.5 to 12.3 years). Seven deaths were recorded. No deaths were related to NSC. Causes of death were second malignancies (non-Hodgkin lymphoma and non-small cell lung cancer) or cardiovasculary/pulmonary disease. One local relapse (4%) occurred in a T1 BCC patient 3.05 years after resection and reconstruction with a paramedian forehead flap. The patient declined further surgery and opted for definitive radiotherapy. To date, the patient is tumor free.

The 5-year OS was 69.5% for the entire cohort and no statistically significant differences were observed between the BCC and cSCC groups (5-year OS: 70.7% \[BCC cohort\] and 60% \[cSCC cohort\]; log-rank *P*=0.54) ([Fig. 2](#f2-ceo-2019-00192){ref-type="fig"}). Furthermore, 5-year OS was not significantly different between surgically reconstructed patients (77.2%) and prosthetically rehabilitated patients (53.6%) (log-rank *P*=0.15). Five-year RFS was not significantly different between the reconstruction cohort 85.7% and prosthesis cohort 100% (log rank *P*=0.45). The 5-year RFS for the entire study population was 90.9% (BCC, 87.5%; cSCC, 100%; log-rank *P*=0.54) ([Fig. 2](#f2-ceo-2019-00192){ref-type="fig"}). The DSS was 100%. Data on HRQoL was collected for an average 1.7 years after surgery. At the time of the survey, 18 of 25 patients (72%) were still alive. Eleven out of 18 (61%) living patients completed all questionnaires. The nasal defects of two patients were prosthetically rehabilitated (18.2%) and the defects were surgically reconstructed in nine patients (81.8%).

CSCC patients (average ROE score, 81.3; standard deviation \[SD\], 20.6) had a higher HRQoL score than BCC patients (average ROE score, 70.8; SD, 20.1), but this difference was not significant. FROI-17 self-confidence subscales were very low for both tumor types, indicating a high degree of self-confidence. Regarding the SF-36 questionnaire, physical functioning scores were significantly lower in the BCC group (average FROI-17 score, 61.9; SD, 31.7) than the cSCC group (91.7; SD, 10.4; *P*=0.044) ([Table 2](#t2-ceo-2019-00192){ref-type="table"}, [Fig. 3](#f3-ceo-2019-00192){ref-type="fig"}). No significant differences were observed in all HRQoL questionnaire scores between surgical reconstruction versus prosthetic rehabilitation and early (T1/2) versus advanced (T3/4) tumor stages. The SF-36 scores in the NSC patient group were significantly lower than those in the normally distributed reference population (n=2,900) for physical functioning (*P*=0.049) and social functioning (*P*\<0.001) ([Fig. 3](#f3-ceo-2019-00192){ref-type="fig"}). The means and standard deviation values for all questionnaires for all patient subgroups are shown in [Table 2](#t2-ceo-2019-00192){ref-type="table"}.

DISCUSSION
==========

The therapy of choice for NSC is surgery. However, the nose has a delicate and complex multilayered structure and prominent localization, which makes reconstruction of post-surgical defects challenging. Functional and aesthetic nasal problems may arise following surgery \[[@b23-ceo-2019-00192]\]. Established guidelines for nasal reconstruction are still lacking \[[@b24-ceo-2019-00192],[@b25-ceo-2019-00192]\]. HRQoL scores are increasingly indispensable for measuring aesthetic and functional rehabilitation after surgery. However, there are still no HRQoL data for patients with multilayered defects in an area as aesthetically prominent as the nose after surgery to treat skin cancer.

So far, only two studies have investigated HRQoL in patients after radical nasal tumor resection with prosthetic rehabilitation alone, and only two studies have evaluated patients after surgical nasal reconstruction alone \[[@b26-ceo-2019-00192]-[@b29-ceo-2019-00192]\]. These studies used the modified surveys University of Washington QoL (UWQoL) and the Nasal Appearance and Function Evaluation Questionnaire (NAFEQ) \[[@b26-ceo-2019-00192],[@b30-ceo-2019-00192],[@b31-ceo-2019-00192]\]. The UWQoL mainly focuses on social and physical function, such as mood, salivation, anxiety, taste, speech, shoulder function, chewing, swallowing, recreation, activity, appearance, and pain. The NAFEQ questionnaire evaluates aesthetic and functional outcomes.

However, the only validated HRQoL questionnaires for conventional rhinoplasty are the FROI-17 and the ROE \[[@b32-ceo-2019-00192],[@b33-ceo-2019-00192]\]. Similar to the NAFEQ, the organ-specific FROI-17 evaluates both functional and aesthetic outcomes after rhinoplasty. The ROE focuses on the cosmetic outcome and the SF-36 assesses social and physical functions.

Twenty-five patients with nonmelanoma NSC were included in this study. There may be some degree of referral bias, which cannot be completely controlled, but surgery is the treatment of choice in our institution. A detailed comparison of major advantages and disadvantages of both rehabilitation strategies is given in [Table 3](#t3-ceo-2019-00192){ref-type="table"} showing that the nasal reconstruction and prostheses are both very viable options depending on tumor stage, biology, and the patient's wishes as well as the experience of the surgeon. To our knowledge, this is the first study to compare two different rehabilitation strategies (prosthetic rehabilitation versus surgical reconstruction) after surgical treatment of advanced NSC with HRQoL analysis. Due to the small number of patients, valid statements on differences in age and gender regarding the HRQoL outcome could not be addressed.

The ROE scores ranged between 70.8 and 81.25, indicating that the aesthetic HRQoL was similar in all subgroups. Compared with average scores of 58.8--83.3 after conventional rhinoplasty, our subgroup ROE findings were high \[[@b33-ceo-2019-00192]-[@b36-ceo-2019-00192]\]. Although the comparison between conventional rhinoplasty and NSC patients is limited, this patient-reported aesthetic result is very satisfactory and quite astonishing \[[@b22-ceo-2019-00192]\].

In contrast to the ROE, a higher FROI-17 score indicates lower satisfaction. The FROI-17 includes functional questions, which complement the aesthetic assessment of the ROE. For the subcohort analysis (cSCC vs. BCC; surgical reconstruction versus prosthesis rehabilitation; T1/2 vs. T3/4), the overall FROI-17 and the subscores general symptoms, nasal symptoms, and self-confidence did not differ significantly.

In the generic SF-36 questionnaire, physical functioning scores were higher in cSCC patients (91.7) than BCC patients (61.9). This might be partly due to different age distribution or different postoperative expectations. We compared our data with a normally distributed reference cohort (which was included in the validation of the SF-36). Physical functioning was good in our NSC patients, but significantly worse than the reference patient cohort. Although organ specific HRQoL were satisfactory, significantly low physical and social functioning scores may indicate restrictions in everyday life. Age and orthopedic disabilities may be responsible for the reduced HRQoL score for the NSC group compared to reference cohort. However, these were not examined due to the low number of the NSC cohort. We believe that the excellent organ-specific HRQoL outcome we observed is a result of our dedicated multidisciplinary approach with extensive rehabilitation counselling before ablative surgery is performed.

The strength of the study that it is the first to address HRQoL in advanced NSC patients. There are, of course, also limitations of this study. Obviously, the study cohort is small, which is due to the low incidence of patients with this particular tumor entity being that far locally advanced to require multilayered excision. There might be a referral bias to this study, as some patients might have been sent for radiotherapy, because they declined rhinectomy. However, we estimate that the proportion is minimal, because the institutional preference in this situation is surgery. Moreover, the assignment of patients the rehabilitation strategy was based on patients' preference and oncological factors as stage, tumor biology and risk factors on histology, and not in a randomized controlled fashion. However, we believe that such a trial would be difficult to conduct, as these patients most likely declined randomization.

Overall oncological outcome is good for nonmelanoma NSC. However, extensive multilayer resections are sometimes necessary to cure the patient which may have high physiological impact on the patients and affect their HRQoL. Despite the worse overall HRQoL outcome (SF-36) than in the control cohort, in terms of organ-specific HRQoL (ROE and FROI-8), we observed a high degree of satisfaction. We believe that this might be a merit of our dedicated multidisciplinary approach with extensive counselling of all rehabilitation options before ablative surgery is performed. Interestingly, the HRQoL outcome between both rehabilitation methods had been comparable. Therefore patient's preference and the experience of the surgeon should be considered when choosing the reconstruction method.

HIGHLIGHTS
==========

• Surgery in advanced nasal skin cancer patients results in an excellent prognosis.

• Quality of life is equal in nasal reconstruction and prosthetic rehabilitation for extensive skin cancer defects.

• Nasal reconstruction and prostheses are both very viable options depending on tumor stage and biology, patient's wishes as well as the experience of the surgeon.
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![(A-C) Partial rhinectomy and reconstruction with a paramedian forehead flap, anterior based septal mucoperichondrious flap, and cartilage graft. (D-F) Total rhinectomy followed by reconstruction with an implant-retained nasal prosthesis (nasal plate of the Epiplating System by Medicon eG, Tuttlingen, Germany; anaplastologist Jörn Brom, Heidelberg, Germany).](ceo-2019-00192f1){#f1-ceo-2019-00192}

![Kaplan-Maier plots for overall survival (OS) and recurrence-free survival (RFS) depending on T1/2 vs. T3/4, basal cell carcinoma (BCC) vs. cutaneous squamous cell carcinoma (cSCC), prosthetic rehabilitation (PR) vs. surgical reconstruction (SR). Disease-specific survival was 100% (not shown).](ceo-2019-00192f2){#f2-ceo-2019-00192}

![Box-plot analysis showing the 36-Item Short Form Health Survey (SF-36) subscores (*P*\<0.05) comparing sub-cohort (cutaneous squamous cell carcinoma \[cSCC\] versus basal cell carcinoma \[BCC\]; surgical reconstruction versus prosthetic rehabilitation, T1/2 versus T3/4, and in the SF-36 to the norm-distributed patient cohort). A higher SF-36 score indicates higher satisfaction. Only significant differences are presented. NSC, nasal skin cancer.](ceo-2019-00192f3){#f3-ceo-2019-00192}

###### 

Surgical and clinicopathological characteristics of the study population

  Characteristics                             Entire cohort (n=25)   Prosthesis cohort (PR, n=7)   Reconstruction cohort (SR, n=18)
  ------------------------------------------- ---------------------- ----------------------------- ----------------------------------
  Age (yr)                                    73 (52--93)            85 (74--92)                   68 (52--93)
  Sex                                                                                              
   Male                                       15 (60.0)              3 (42.9)                      12 (66.7)
   Female                                     10 (40)                4 (57.1)                      6 (33.3)
  Histology                                                                                        
   BCC                                        20 (80)                5 (71.4)                      15 (83.3)
   cSCC                                       5 (20)                 2 (28.6)                      3 (16.7)
  T stage                                                                                          
   T1/2                                       17 (68.0)              3 (42.9)                      14 (77.8)
   T3/4                                       8 (32.0)               4 (57.1)                      4 (22.2)
  N stage                                                                                          
   N0                                         25 (100)               7 (100)                       18 (100)
  M stage                                                                                          
   M0                                         25 (100)               7 (100)                       18 (100)
  Questionnaire (FROI-17, ROE, and SF-36)                                                          
   No response                                7 (28.0)               1 (14.3)                      6 (33.3)
   Response                                   11 (44.0)              2 (28.6)                      9 (50.0)
   Excluded due to death                      7 (28.0)               4 (57.1)                      3 (16.7)
  5-Year overall survival rate (%)            69.5                   53.6                          77.2
  5-Year disease-specific survival rate (%)   100                    100                           100
  5-Year recurrence-free survival rate (%)    90.9                   100                           85.7

Values are presented as mean (range) or number (%).

PR, prosthetic rehabilitation; SR, surgical reconstruction; BCC, basal cell carcinomas; cSCC, cutaneous squamous cell carcinomas; FROI-17, Functional Rhinoplasty Outcome Inventory 17; ROE, Rhinoplasty Outcome Evaluation; SF-36, 36-Item Short Form Health Survey.

###### 

FROI-17, ROE, and SF-36 scales

  Variable                      Prosthetic rehabilitation (n=7)   Surgical reconstruction (n=18)   *P*-value
  ----------------------------- --------------------------------- -------------------------------- -----------
  FROI-17                                                                                          
   Overall score                15.0±0.0                          25.6±29.2                        0.750
   Nasal symptom                10.0±12.4                         22.2±20.8                        0.610
   General symptom              20.0±14.4                         21.4±29.1                        0.965
   Self-confidence              0.0±0.0                           20.0±32.7                        0.588
  ROE                           79.2±0.0                          72.4±20.6                        0.766
  SF-36                                                                                            
   Physical functioning         55.0±35.4                         73.3±30.4                        0.469
   Physical role functioning    50.0±70.7                         66.7±50.0                        0.695
   Bodily pain                  94.4±7.9                          72.8±31.5                        0.378
   General health               52.5±3.5                          64.4±26.2                        0.558
   Vitality                     55.0±0.0                          70.0±28.9                        0.640
   Social functioning           43.8±8.8                          50.0±11.6                        0.503
   Emotional role functioning   66.7±47.1                         79.2±39.6                        0.707
   Mental health                72.0±0.0                          69.0±16.0                        0.864
                                                                                                   
                                **BCC (n=20)**                    **cSCC (n=5)**                   
                                                                                                   
  FROI-17                                                                                          
   Overall score                25.8±29.1                         13.8±0.0                         0.717
   Nasal symptom                21.7±21.2                         13.3±0.0                         0.730
   General symptom              26.3±29.7                         6.3±8.8                          0.404
   Self-confidence              21.7±35.4                         5.0±7.1                          0.553
  ROE                           70.8±20.1                         81.3±20.6                        0.541
  SF-36                                                                                            
   Physical functioning         61.9±31.7                         91.7±10.4                        0.044
   Physical role functioning    62.5±51.8                         66.7±57.7                        0.910
   Bodily pain                  72.2±33.6                         88.9±11.1                        0.248
   General health               57.1±25.5                         73.3±17.6                        0.352
   Vitality                     63.3±30.9                         78.3±20.2                        0.478
   Social functioning           48.2±13.4                         50.0±0.0                         0.829
   Emotional role functioning   66.7±43.0                         100.0±0.0                        0.086
   Mental health                66.0±17.7                         76.0±4.0                         0.380
                                                                                                   
                                **NSC cohort (n=25)**             **SF-36 cohort (n=2,900)**       
                                                                                                   
  SF-36                                                                                            
   Physical functioning         70.0±30.3                         84.2±23.8                        0.049
   Physical role functioning    63.6±50.5                         80.6±34.5                        0.292
   Bodily pain                  76.8±29.6                         77.0±28.5                        0.978
   General health               62.0±23.7                         64.1±23.5                        0.777
   Vitality                     68.3±27.5                         61.9±19.1                        0.316
   Social functioning           48.8±10.9                         87.7±19.5                        \<0.001
   Emotional role functioning   76.7±38.7                         87.7±29.0                        0.228
   Mental health                69.3±15.0                         72.9±17.2                        0.541

Values are presented as mean±standard deviation.

FROI-17, ROE, and SF-36 scales after prosthetic rehabilitation (n=7) vs. surgical reconstruction (n=18) in all patients (T1-4), BCC (n=20) vs. cSCC patients (n=5), and NSC cohort (n=25) vs. the normally distributed SF-36 reference population (n=2,900). A higher ROE score indicates higher satisfaction. A higher FROI-17 score indicates lower satisfaction. P\<0.05 were considered statistically significant.

FROI-17, Functional Rhinoplasty Outcome Inventory 17; ROE, Rhinoplasty Outcome Evaluation; SF-36, 36-Item Short Form Health Survey; SD, standard deviation; BCC, basal cell carcinomas; cSCC, cutaneous squamous cell carcinomas; NSC, nasal skin cancer.

###### 

Comparison of advantage and disadvantage in prosthetic rehabilitation versus surgical reconstruction

  Variable                                                                                     Prosthetic rehabilitation                                                                                Surgical reconstruction
  -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  Advantage                                                                                    • Simple and fast surgical procedure for implant placeme (operating time approximately 20--30 minutes)   • Psychological benefit of using patient's own tissue
  • No donor site morbidity/scars                                                              • No need for maintenance or specialized care                                                            
  • Short rehabilitation time (fitting after a healing period of 6                             • Defect is eliminated and no longer visible.                                                            
  • Predictable cosmesis of prosthesis                                                         • Follows color change of adjacent skin with temperature, emotion and sun exposure                       
  • Prosthesis may be changed according to patient wishes.                                                                                                                                              
  • Ease of oncological follow-up to detect local recurrence                                                                                                                                            
  Disadvantage                                                                                 • Prothesis is a "foreign body."                                                                         • Multiple stages of surgical reconstruction under general anesthesia with longer operation time
  • Patients keep the defect.                                                                  • Longer healing time with three surgical stages of 3--6 months                                          
  • Risk of losing the prosthesis with inadvertent contact                                     • Possible surgical complications with reconstruction, especially in irradiated patients and smokers     
  • Prosthesis is removed for sleeping (patient wears a light bandage).                        • Possible need for secondary refinement surgery                                                         
  • Prosthesis may exhibit color mismatch with seasonal cha complexion or cigarette smoke.     • Additional scars outside the nasal region                                                              
  • Necessity of a new prosthesis every 2 years due to degr and/or slight defect changes       • Malignant precursor lesion may be transposed (field cancerization with UV exposure).                   
  • Cost for initial and repetitive manufacturing                                              • Cosmetic result less predictable                                                                       
  • Personal hygiene for percutaneous parts of implants (however minimal for nasal implants)   • Oncological follow-up less easy (may need endoscopy and imaging)                                       
  • Magnets have to be temporarily removed for MRI (titanium implants are MRI conditional).                                                                                                             

UV, ultraviolet; MRI, magnetic resonance imaging.
